-
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges
Monday, September 9, 2024 - 10:12am | 583Biogen Inc. (NASDAQ:BIIB) and Eisai Ltd’s (OTC:ESALY) Alzheimer’s drug Leqembi (lecanemab) is reportedly offering hope for patients in the early stages of the disease despite it not being a cure. For many, like Mississippi English professor Missie Meeks, the treatment is helping to slow...
-
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
Wednesday, July 24, 2024 - 3:12pm | 539Vigil Neuroscience Inc. (NASDAQ:VIGL) released interim data on Wednesday from its ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers. VG-3927 is a novel small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus...
-
Disappointing Drug News Sends Biogen And XOMA Shares Down
Wednesday, July 22, 2015 - 10:34am | 560Shares of Biogen Inc (NASDAQ: BIIB) were trading lower by more than 3 percent Wednesday morning after the company reported mixed results in a Phase 1 Alzheimer's study in which a 6MG dose failed to significantly slow mental decline. "We are encouraged by these new results, which...